eligibility_summary
Inclusion: MM (IMWG), ECOG 0–2, prior AEs ≤G1, compliant. SS2: post‑induction ≥PR, ASCT ≤100 d, high‑risk cytogenetics, lenalidomide REMS, contraception. SS4: prior PI+IMiD+anti‑CD38, no SOC options. Exclusion: CNS/CV/pulmonary issues, infections (HBV/HCV/HIV/COVID), high‑dose steroids, autoimmune/HLH, hypersensitivity, strong CYP3A modulators, uncontrolled HTN/DM, neuropathy >G2, prior FcRH5/iberdomide, recent CAR‑T/SCT, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2 platform trial in multiple myeloma testing: 1) Cevostamab (IV bispecific T‑cell–engaging antibody) that binds FcRH5 on malignant plasma cells and CD3 on T cells to induce cytotoxicity, combined with lenalidomide (oral IMiD, cereblon modulator causing IKZF1/IKZF3 degradation, enhancing T/NK activation) as post‑transplant maintenance in high‑risk patients. 2) Cevostamab plus iberdomide (oral next‑gen CELMoD, potent cereblon modulator driving Ikaros/Aiolos degradation, boosting T/NK function) ± dexamethasone (corticosteroid, lympholytic/anti‑inflammatory) in relapsed/refractory MM. Tocilizumab (anti‑IL‑6R mAb) is available to treat cytokine release syndrome. Targets/pathways: FcRH5+ plasma cells, CD3 T‑cell activation, CRL4–cereblon E3 ligase pathway (Ikaros/Aiolos degradation), and IL‑6 signaling during CRS.